Table 3

Baseline and 3-month and 6-month tocilizumab therapy criteria in 13 patients with axial spondyloarthritis

Pt 1

Pt 2

Pt 3

Pt 4

Pt 5

Pt 6

Pt 7

Pt 8

Pt 9

Pt 10

Pt 11

Pt 12

Pt 13


BASDAI, 0 to 100

M0

78

90

72

42

77

63

80

48

49

59

48

72

57

M3 (change from M0; %)

+6

-19

+1

-15

+1

-1.6

+3.8

-2

+4

-5

+43

-10

-12

M6 (change from M0; %)

NA

NA

NA

-17

NA

NA

NA

NA

-6

-15

+17

NA

NA

ASDAS

M0

4.87

3.35

3.24

3.37

5

5.36

3.8

2.98

2.68

2.41

2.94

3.2

4.12

M3 (change from M0; units)

-1.6

-0.8

-0.75

-0.04

-1.5

-1.7

-0.3

-0.24

-1.36

-0.43

-0.35

+0.02

-1.96

M6 (change from M0; units)

NA

NA

NA

-1.17

NA

NA

NA

NA

-1.02

-0.61

-0.23

NA

NA

BASFI, 0 to 100

M0

86

95

63

32

72

MD

MD

59.5

50

57

59

28

36

M3 (change from M0; %)

-8

-8

+16

+3

+28

MD

MD

-6

+6

-7

+30

-29

+47

M6 (change from M0; %)

NA

NA

NA

+22

NA

MD

MD

NA

0

-7

-34

NA

NA

Pain VAS, 0 to 10

M0

9

10

7

4

7

7

8

4

5

6

5

7

4

M3 (change from M0; units)

+0.5

-3

+1

0

0

-0.2

+1

+3

+1

-2

0

-1

0

M6 (change from M0; units)

NA

NA

NA

-1

NA

NA

NA

NA

+1

-2

+2

NA

NA

CRP (mg/dl)a

M0

29

0

2

46

35

96

10

10.4

1

1

1.8

3

35.2

M3 (absolute value)

0.3

0

0

NA

3

4

1

< 5

NA

NA

NA

3

1

M6 (absolute value)

NA

NA

NA

6

NA

NA

NA

NA

0

1

0.6

NA

NA

ESR (mm)a

M0

71

9

8

47

35

104

21

12

9

8

1

11

15

M3 (absolute value)

10

2

4

NA

2

2

1

3

NA

NA

NA

3

1

M6 (absolute value)

NA

NA

NA

5

NA

NA

NA

NA

4

1

1

NA

NA


BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS, Assessment of SpondyloArthritis International Society-endorsed disease activity score; BASFI, Bath Ankylosing Spondylitis Functional Index; VAS, visual analogue scale; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; M0, month 0 (baseline); M3, month 3; M6, month 6; MD, missing data; NA, not available; Pt, Patient. aFor CRP and ESR, the table shows only the values at baseline (M0) and at last follow-up (M3 or M6).

Lekpa et al. Arthritis Research & Therapy 2012 14:R53   doi:10.1186/ar3766

Open Data